Cancer Vaccine Institute News

On October 30, the FDA granted accelerated approval to Voceryq, the first-ever plasmid DNA-based immunotherapy, developed by Inovio Pharmaceuticals. The treatment delivers two plasmids to help the immune system target cells infected with human papillomavirus (HPV), which are responsible for recurrent respiratory papillomatosis (RRP). The FDA’s approval marks an important milestone for DNA-based therapeutics and could help advance research in this field. Cancer Vaccine Institu

Breast cancer is one of the most common cancers and the second leading cause of cancer-related death among women. While advances in targeted therapies have improved patient outcomes for several breast cancer subtypes, metastatic triple-negative breast cancer (TNBC) remains one of the most challenging forms of the disease to treat. Although immune checkpoint inhibitors (ICIs) combined with chemotherapy have improved survival for some patients with metastatic TNBC, this benefit

The biggest challenge in ovarian cancer isn’t getting to remission - it’s staying there. Recurrence rates are high, especially for advanced disease. Nineteen-year survivor and CVI vaccine recipient Jamie Crase captures that stark reality: “Stage 4 ovarian cancer has a 90-95% chance of recurrence after the initial treatment. The odds were not in my favor.” At the Cancer Vaccine Institute, we are changing the odds in the favor of Jamie and all patients diagnosed with this deadl

The Cancer Vaccine Institute (CVI) is advancing the emerging field of cancer research, developing vaccines to intercept cancer before it becomes invasive. We have developed WOKVAC, a DNA-based vaccine designed to target three proteins - HER2, IGFBP-2, and IGF-1R - highly expressed in most Ductal Carcinoma In Situ (DCIS), a preinvasive form of breast cancer. Although not immediately life-threatening, 20% of DCIS lesions may progress to invasive cancer. Patients diagnosed with

The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have partnered to raise nearly $200 million to fund cancer vaccine clinical trials, including mRNA-based approaches for patients at high risk for tumor recurrence. Dr. Nora Disis In a recent article from Lancet Oncology, Dr. Nora Disis, Director of the Cancer Vaccine Institute (CVI), called the initiative a promising start, but commented that the scale of the investment remains sma